Primary angioplasty and pharmaco-invasive strategies in the treatment of ST-elevated myocardial infarction
https://doi.org/10.15829/1728-8800-2019-2-94-103
Abstract
The lecture is devoted to the choice of tactics and the rules of reperfusion therapy for ST-elevated myocardial infarction. Since the time of reperfusion is crucial for the survival of these patients and the preservation of a viable myocardium, proper organization of care and strict adherence to the guidelines for drug-induced and non-drug interventions is necessary. The lecture substantiates the tactics of pharmaco-invasive intervention, the choice of thrombolytic agent, provides data on indications and contraindications for thrombolytic therapy, dosing regimen of thrombolytic drugs, other antiplatelet and anticoagulant drugs required for reperfusion. Knowledge of current guidelines should help reduce ischemia time and cases of unjustified refusal to effective interventions.
About the Authors
M. G. Glezer
I. M. Sechenov First Mosco w State Medical University
Russian Federation
Russian Federation
Moscow
E. I. Astashkin
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Moscow
References
1. Clinical recommendations Diagnosis and treatment of patients with acute myocardial infarction with ST-segment elevation ECG. Cardiovascular Therapy and Prevention. 2007;6(8), Prilozhenie 1. (In Russ.)
2. Emergency. Clinical recommendations. Ed. S. F. Bagnenko. M.: GEOTAR-Media, 2015. 872 p. (in Russ.). ISBN 978-5-97043447-5.
3. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77 doi:10.1093/eurheartj/ehx393.
4. Danchin N, Coste P, Ferrieres J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction. Data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118(3):268-76. doi:10.1161/CIRCULATIONAHA.107762765.
5. Vasil'eva EYu, Plavunov NF, Kalinskaya AI, et al. Organization of “heart attack network” in Moscow and the results of its work for a five-year period. Endovaskulyarnaya hirurgiya. 2018;5(2):288-94. (In Russ.)
6. Barbarash OL, Kashtalap VV. The place of pharmacoinvasive management in patients with ST-elevation acute coronary syndrome in Russia. Kardiologiia. 2014;54(9):79-85. (In Russ).
7. Artamonova GV, Heraskov VYu, Kryuchkov DV, et al. The approach to organizing care for patients with myocardial infarction is the “Kemerovo model”. Kompl probl serdechno-sosudistyh zabol. 2013;1:55-9. (In Russ)
8. . Bokeriya LA, Klyuchnikov IV, CHigogidze NA, et al. The effect of time after thrombolytic therapy on the results of coronary artery stenting in patients with myocardial infarction. Byul NCSSKH im. A. N. Bakuleva RAMN. 2013;6:46-50. (In Russ.)
9. Pinto DS, Frederick PD, Chakrabarti AK, et al, National Registry of Myocardial Infarction Investigators. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation. 2011;124(23):2512-21. doi:10.1161/CIRCULATIONAHA.111.018549.
10. Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87. doi:10.1056/NEJMoa1301092.
11. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311-22. doi:10.1016/S0140-6736(94)91161-4.
12. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996 Sep 21;348(9030):771-5. doi:10.1016/S0140-6736(96)02514-7.
13. White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356(9247):2028-30. doi:10.1016/S0140-6736(00)03397-3.
14. Carville S, Harker M, Henderson R, Gray H. Guideline Development Gro Acute management of myocardial infarction with ST-segment elevation: summary of NICE guidance. BMJ. 2013 Jul 10;347:f4006. doi:10.1136/bmj.f4006.
15. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;61(4):e78-140. doi:10.1016/j.jacc.2012.11.019.
16. Danchin N, Blanchard D, Steg PG, et al.; USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation. 2004;110:1909-15. doi:10.1161/01.CIR.0000143144.82338.36.
17. 17 Murphy SA, Gibson CM, Van de Werf F, et al. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol. 2002;90(1):51-4. doi:101016/S0002-9149(02)02387-1.
18. Armstrong PW, Zheng Y, Westerhout CM, et al. STREAM investigators. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. Am Heart J. 2015;169(6):890-8.e1. doi:10.1016/j.ahj.2015.03.011.
19. Lanaro E, Caixeta A, Soares JA, et al. Influence of gender on the risk of death and adverse events in patients with acute myocardial infarction undergoing pharmacoinvasive strategy. J Thromb Thrombolysis. 2014;38(4):510-6. doi:101007/s11239-014-1072-7.
20. Bainey KR, Ferguson C, Ibrahim QI, et al. Vital Heart Response Registry Investigators. Impact of reperfusion strategy on aborted myocardial infarction: insights from a large Canadian ST-Elevation Myocardial Infarction Clinical Registry. Can J Cardiol. 2014;30(12):1570-5. doi:10.1016/j.cjca.2014.08.021.
21. Dianati Maleki N, Van de Werf F, Goldstein P, et al. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014;100(19):1543-9. doi:10.1136/heartjnl-2014-306023.
22. Shavadia J, Zheng Y, Dianati Maleki N, et al. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015;4(8):e002049. doi: 10.1161/JAHA.115.002049.
23. Bundhun PK, Janoo G, Chen MH. Bleeding events associated with fibrinolytic therapy and primary percutaneous coronary intervention in patients with STEMI: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(23): e3877. doi:10.1097/MD.0000000000003877.
24. Guillermin A, Yan DJ, Perrier A, Marti C. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Arch Med Sci. 2016;12(6):1181-7. doi:10.5114/aoms.2016.58929.
25. Liu F, Guo Q, Xie G, et al. Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-Analysis. PLoS One. 2015;10(11):e0141855. doi:10.1371/journal.pone.0141855.
26. Jaffe R, Halon DA, Karkabi B, et al. Thrombolysis Followed by Early Revascularization: An Effective Reperfusion Strategy in Real World Patients with ST-Elevation Myocardial Infarction Cardiology. 2007;107:329-36. doi:10.1159/000099070.
27. Rashid MK, Guron N, Bernick J, et al. Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System. JACC Cardiovasc Interv. 2016;9(19): 2014-20. doi:10.1016/j.jcin.2016.07.004.
28. Sim DS, Jeong MH, Ahn Y, et al. Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis. Circ Cardiovasc Interv. 2016;9(9). pii:e003508. doi:10.1161/CIRCINTERVENTIONS.115.003508.
29. Pu J, Ding S, Ge H, et al. EARLY-MYO Investigators. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation. 2017;136(16):1462-73. doi:10.1161/CIRCULATIONAHA.117.030582.
30. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006;114:2019-25. doi:10.1161/CIRCULATIONAHA.106.638353.
31. Siddiqi TJ, Usman MS, Khan MS, et al. Meta-Analysis Comparing Primary Percutaneous Coronary Intervention Versus Pharmacoinvasive Therapy in Transfer Patients with ST-Elevation Myocardial Infarction. Am J Cardiol. 2018;122(4):542-7. doi:10.1016/j.amjcard.2018.04.057.
32. Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018;202:89-96. doi:10.1016/j.ahj.2018.02.017.
Review
For citations:
Glezer M.G., Astashkin E.I. Primary angioplasty and pharmaco-invasive strategies in the treatment of ST-elevated myocardial infarction. Cardiovascular Therapy and Prevention. 2019;18(2):94-103. (In Russ.) https://doi.org/10.15829/1728-8800-2019-2-94-103
Views:
862
Email this article 
